QST-Pupillometry in Sickle Cell Disease Patients (QST)

January 17, 2020 updated by: Julia Finkel

Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.

There has been little progress for effective treatment of pain in sickle cell disease (SCD) patients. Many organizations have recognized that understanding the causes and reducing the burden of pain in SCD is critical in order to improve the quality of life in SCD patients. As patients with SCD face the challenge of living with both acute and chronic pain which is often improperly treated, our translational and interdisciplinary project aims to identify objective measures of pain sensitivity and its biochemical and genetic correlates. We hypothesize that SCD patients will have decreased tolerance to thermal and electrical stimuli.

Study Overview

Study Type

Observational

Enrollment (Actual)

96

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Children's National Medical Center
      • Washington, District of Columbia, United States, 20010
        • Children's National Health System

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 30 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

SCD patients referred to the Pain Medicine clinic, either outpatient or inpatient.

Description

Inclusion Criteria:

  • SCD with severe phenotype (HbSS, HbSbeta0 thalassemia, HbSOArab)
  • Relatives of SCD patients who do not have sickle cell trait or SCD; healthy controls

Exclusion Criteria:

  • Completed overt clinical stroke or transient ischemic attack;
  • Known severe vasculopathy or Moyamoya disease on brain MRA (Magnetic Resonance Angiography).
  • history of having consumed alcohol within the last 12 hours prior to testing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
High frequency pain group
39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
Low Pain Frequency group
39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
Healthy control group
39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
Pain Crisis group
30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
Pain Service group
10 patients without sickle cell disease admitted to the pain service.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measuring thermal responsiveness (perception and tolerance) in the outpatient groups.
Time Frame: change between baseline and at 90day follow-up
Using a TSA (thermal sensory analyzer), the patients hot and cold perception and tolerance will be measured in the outpatient groups (high-pain and low-pain frequency and controls).
change between baseline and at 90day follow-up
Measuring thermal responsiveness (perception and tolerance) in the inpatient groups.
Time Frame: change over 8 consecutive days
Using a TSA thermal sensory analyzer, the patients hot and cold perception and tolerance will be measured in the inpatient groups (pain crisis and pain service).
change over 8 consecutive days
Measure mechanical responsiveness in outpatient groups.
Time Frame: change between baseline and 90 day follow-up
Using the Wagner PPIX 50 Pressure device, patient's tolerance to pressure is assessed in the outpatient groups (high-pain and low-pain frequency and controls).
change between baseline and 90 day follow-up
Measure mechanical responsiveness in inpatient groups.
Time Frame: change over 8 consecutive days
Using the Wagner PPIX 50 Pressure device, patient's tolerance to pressure is assessed in the inpatient groups (pain crisis and pain service).
change over 8 consecutive days
Measuring the pupil responsiveness in outpatient groups.
Time Frame: change between baseline and 90 day follow-up
Using the Pupillometer device, pupil responses are assessed in the outpatient groups (high-pain and low-pain frequency and controls).
change between baseline and 90 day follow-up
Measuring the pupil responsiveness in inpatient groups.
Time Frame: change over 8 consecutive days
Using the Pupillometer device, pupil responses are assessed in the inpatient groups (pain service and pain crisis).
change over 8 consecutive days
Measuring electrical sensitivity in outpatient groups.
Time Frame: change between baseline and at 90day follow-up
Using the Neurometer device, to assess electrical sensory perception and tolerance in the outpatient groups (high-pain and low-pain frequency and control).
change between baseline and at 90day follow-up
Measuring electrical sensitivity in inpatient groups.
Time Frame: change over 8 consecutive days
Using the Neurometer device, to assess electrical sensory perception and tolerance in the outpatient groups (pain service and pain crisis).
change over 8 consecutive days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Julia Finkel, MD, Children's National Health System

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2013

Primary Completion (Actual)

November 1, 2018

Study Completion (Actual)

November 1, 2018

Study Registration Dates

First Submitted

September 13, 2013

First Submitted That Met QC Criteria

September 14, 2014

First Posted (Estimate)

September 16, 2014

Study Record Updates

Last Update Posted (Actual)

January 21, 2020

Last Update Submitted That Met QC Criteria

January 17, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)

  • RTI International
    Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators
    Enrolling by invitation
    Primary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditions
    United States

Clinical Trials on Quantitative sensory testing

3
Subscribe